Six years later, an 80-year-old woman stepped into Dr. Steele’s clinic with anxiety, depression, high blood pressure, arthritis, and a fresh dementia diagnosis. Though he had never treated dementia, ...

Conference call and webcast to be held at 8 a.m. ET on December 16, 2025 ...

Findings provide scientific insights into the contributions of IDO1 and PD-L1 vaccination to PD-1 blockade for the treatment of metastatic melanoma; Five-year analysis of median p ...

Clinical Development Program Appropriate for Rolling BLA . Submission Expected by the End of 2025. CANTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Na ...

Allogene’s investigational AlloCAR T oncology products utilize Cellectis technologies. Cemacabtagene ansegedleucel (cema-cel) was developed based on an exclusive license granted by Cellectis to ...

On November 25, 2025, Claret European Growth Capital Fund III SCSp converted its portion of the Tranche A convertible OCABSA resulting in the issuance of 392,695 ordinary shares of the Company.

Vivos management will discuss the strategic business model pivot and operational execution; the market opportunity and competitive environment; and Vivos’ growth and financial strategies. To register ...

The Tribunal ruled on a partial termination of the License Agreement with respect to product UCART19 V1 (also referred to as “ALLO-501” by Allogene) and provided that Cellectis shall, at Allogene’s ...

CONSHOHOCKEN, Pa., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the J.P. Morgan Annual Healthcare Conference on ...

The securities described above will be offered by Kyverna pursuant to an effective “shelf” registration statement on Form S-3 (File No. 333-286180) that was filed with the Securities and Exchange ...

Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) ...

The shares of Common Stock underlying the Tranche A Warrants have been registered by Fractyl under the Securities Act of 1933, as amended, and are covered by a registration statement filed with, and ...